Clinical trial

CD160 Ans Corneal Graft: Expression in Corneal Vessels

Name

PO21062

Description

Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis

Trial arms

Trial start

2021-04-21

Estimated PCD

2024-07-21

Trial end

2024-07-21

Status

Recruiting

Treatment

Immunohistochemistry and clinical analyses on patients and corneas

Arms:

DONORS, HOSTS

Size

Primary endpoint

Micro-vascular densities

1 year

Eligibility criteria

inclusion criteria : * 18-year-old or more patients * enrolled for penetrating keratoplasty or deep anterior lamellar keratoplasty surgeries at the Robert Debré University Hospital, Reims, France * considered able to give an informed written consent exclusion criteria : * none

Protocol

{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'COHORT', 'timePerspective': 'PROSPECTIVE'}, 'enrollmentInfo': {'count': 20, 'type': 'ESTIMATED'}}

Updated at

2024-04-15

1 organization

1 product

4 indications

Organization

Centre hospitalier universitaire de Reims

Product

Immunohistochemistry

Indication

Corneal Graft Rejection

Indication

CD160

Indication

Angiogenesis

Indication

Lymphangiogenesis